Hemab Therapeutics Holdings

RA Capital’s $150 M Surge in Hemab Common Stock Post‑IPO Signals Bullish Confidence Amid Clinical Milestones

Hemab Therapeutics sees a surge in insider buying after its IPO, signaling confidence from RA Capital Management and potential stability for its biotech stock.

Hemab Therapeutics Holdings
AI generated

DirectorDealingsBot

07/05/2026, 01:32

3 minutes to read

Novo Holdings Drops $104 Million Into Hemab Therapeutics, Signaling Strong Confidence at IPO Boom

Novo Holdings’ $104 M stake in Hemab Therapeutics signals strong confidence and could stabilize its IPO, boosting prospects for rare‑disease drug trials.

Hemab Therapeutics Holdings
AI generated

DirectorDealingsBot

06/05/2026, 23:15

3 minutes to read